Abstract 2299
Background
Chemoradiation is the current standard of care for advanced cervical cancer, however radiation is associated with long term side effects that may impair the quality of life of survivors. Recent findings from observational and case series suggest that women with stage IB2, IIA, and IIB who respond to neoadjuvant chemotherapy might be a candidate for radical surgery as the definitive treatment. This approach can reduce long-term complications associated with chemoradiation and improve patient quality of life.
Trial design
Eligible patients are women aged ≥ 18y diagnosed with invasive cervical cancer stages IB2, IIA or IIB. The stage will be assessed by clinical examination and confirmed by pelvic MRI, CT of upper abdomen and CT of thorax. ECOG PS 0-1 and adequate organ function are required. Two hundred and forty-four patients will be randomly assigned to one of two arms. In arm 1, patients will receive standard chemoradiation (cisplatin 40mg/m2 IV: D1, D8, D15, D29 and D36 in concomitancy with external radiation 50.4Gy fractionated in 28 sessions of 1,8Gy followed by brachytherapy in four insertions of 7 Gy). In arm 2, patients will receive intravenous neoadjuvant chemotherapy (cisplatin 75mg/m2 D1 plus paclitaxel 80mg/m2) D1, D8 e D15, each 21 days, 3 cycles. After each cycle, the patient will be evaluated to verify toxicity and tumor response. After the third cycle, the patients with a complete clinical response or substantial tumor reduction (tumor restricted to cervix ≤4 cm), confirmed by pelvic MRI will undergo Piver-Rutledge class III abdominal hysterectomy and pelvic lymphadenectomy 3-6 weeks after the last cycle. Patients with tumor progression or severe toxicity after any cycle of neoadjuvant chemotherapy, or with inoperable tumor after the third cycle of neoadjuvant chemotherapy will be treated with definitive standard chemoradiation. The primary end point will be 5-years overall survival. Secondary endpoints will include survival free of disease, the rate of operability and complete pathological response in the neoadjuvant arm. The study is ongoing; one patient has been included, and three more are under preliminary evaluation for eligibility.
Clinical trial identification
UTN: U1111-1213-5169.
Legal entity responsible for the study
Division of Gynecologic Oncology - Department of Gynecology and Obstetrics - Ribeirão Preto Medical School - University of São Paulo.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4679 - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Presenter: Chung-Han Lee
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5379 - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks
Presenter: Armin Meier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5394 - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System
Presenter: Ankur Parikh
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5884 - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies
Presenter: Yali Li
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5912 - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.
Presenter: Blanca Torrejón
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1168 - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs
Presenter: Nasha Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3071 - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma
Presenter: Muhammad Khattak
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4062 - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
Presenter: Yu-Zhen Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4801 - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multi-center study
Presenter: Tian Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4874 - Dissecting Gastric Cancer biology and how and when to use immunotherapy
Presenter: Meghna Das Thakur
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract